Y-Intercept (HK)
CTNM icon

Y-Intercept (HK)’s Contineum Therapeutics CTNM Stock Holding History

Y-Intercept (HK)’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.32M Buy
+98,428
New +$1.47M 0.03% 857
2025
Q3 		– Sell
-35,156
Closed -$140K – 2135
2025
Q2 		$140K Buy
+35,156
New +$153K ﹤0.01% 1506

Other funds holding CTNM

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Torren Management
Torren Management San Diego, California $201M AUM 16.25% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

Y-Intercept (HK)'s CTNM Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 98,428 shares worth $1.32M. The stake represents 0.03% of the portfolio and ranks #857 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CTNM as recently as Q2 2025.

Y-Intercept (HK) first reported a position in CTNM in Q2 2025 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Y-Intercept (HK) held 98,428 shares of Contineum Therapeutics worth $1.32M as of Q3 2026.
  • Contineum Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
  • Contineum Therapeutics made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #857 holding.
  • Y-Intercept (HK) first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.